Citadel Advisors
OLMA icon

Citadel Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

Citadel Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.06M Buy
137,900
+33,100
+32% +$737K ﹤0.01% 6017
2025
Q4 		$2.62M Buy
+104,800
New +$1.86M ﹤0.01% 5428
2025
Q2 		– Sell
-6,300
Closed -$23.7K – 14330
2025
Q1 		$23.7K Sell
6,300
-15,200
-71% -$76.4K ﹤0.01% 13021
2024
Q4 		$125K Buy
21,500
+15,200
+241% +$152K ﹤0.01% 11127
2024
Q3 		$75.2K Sell
6,300
-25,900
-80% -$331K ﹤0.01% 11477
2024
Q2 		$348K Buy
32,200
+15,300
+91% +$166K ﹤0.01% 8845
2024
Q1 		$191K Sell
16,900
-12,900
-43% -$166K ﹤0.01% 10395
2023
Q4 		$418K Buy
29,800
+7,600
+34% +$102K ﹤0.01% 8477
2023
Q3 		$274K Buy
22,200
+9,200
+71% +$93.8K ﹤0.01% 9330
2023
Q2 		$117K Buy
+13,000
New +$78.5K ﹤0.01% 10691
2023
Q1 		– Sell
-20,000
Closed -$49K – 15269
2022
Q4 		$49K Sell
20,000
-15,200
-43% -$44.3K ﹤0.01% 12167
2022
Q3 		$97K Sell
35,200
-12,600
-26% -$53.4K ﹤0.01% 11120
2022
Q2 		$195K Buy
47,800
+30,200
+172% +$95.8K ﹤0.01% 10720
2022
Q1 		$75K Sell
17,600
-18,700
-52% -$103K ﹤0.01% 12523
2021
Q4 		$340K Buy
+36,300
New +$752K ﹤0.01% 10644

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Citadel Advisors's OLMA Position: Q1 2026 in Review

Citadel Advisors reduced its Olema Pharmaceuticals (OLMA) stake by 25% in Q1 2026, selling an estimated $6.57M and leaving 905,332 shares worth $13.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2828.

Citadel Advisors first reported a position in OLMA in Q4 2020 and has held it in 22 quarters since. The position peaked at $69M in Q4 2020. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Citadel Advisors held 905,332 shares of Olema Pharmaceuticals worth $13.5M as of Q1 2026.
  • Citadel Advisors sold 294,975 Olema Pharmaceuticals shares in Q1 2026, an estimated $6.57M.
  • Olema Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2828 holding.
  • Citadel Advisors first reported a position in Olema Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Citadel Advisors's Olema Pharmaceuticals position peaked at $69M in Q4 2020.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.